Angiogenesis as a strategic target for ovarian cancer therapy-Reference-Cited by-同舟云学术

Angiogenesis as a strategic target for ovarian cancer therapy

Published:2008-02-12 Issue:4 Volume:5 Page:194-204
ISSN:1743-4254
Container-title:Nature Clinical Practice Oncology
language:en
Short-container-title:Nat Rev Clin Oncol

Author:

Spannuth Whitney A,Sood Anil K,Coleman Robert L

Publisher

Springer Science and Business Media LLC

Subject

Oncology,General Medicine

Link

http://www.nature.com/articles/ncponc1051.pdf

Reference89 articles.

1. American Cancer Society (2007) Cancer Facts and Figures 2007. Atlanta, GA: American Cancer Society

2. du Bois A et al. (2003) A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95: 1320–1329

3. Gore ME (2001) Treatment of relapsed epithelial ovarian carcinoma. In: ASCO 2001 Education Book, 468–476 (Ed MC Perry) Alexandria, VA: American Society of Clinical Oncology

4. Jain RK et al. (2006) Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 3: 24–40

5. Folkman J (1990) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82: 4–6

Cited by 142 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The novel drug candidate S2/IAPinh improves survival in models of pancreatic and ovarian cancer;Scientific Reports;2024-03-16

2. Exosomes: A Cutting-Edge Theranostics Tool for Oral Cancer;ACS Applied Bio Materials;2024-02-23

3. Theranostic signature of tumor-derived exosomes in cancer;Medical Oncology;2023-10-05

4. Combat Against Gynecological Cancers with Blood Vessels as Entry Point: Anti-Angiogenic Drugs, Clinical Trials and Pre-Clinical Nano-Delivery Platforms;International Journal of Nanomedicine;2023-06

5. Exosomes: Mediators in microenvironment of colorectal cancer;International Journal of Cancer;2023-02-23